Clinical Trial Update: Atazanavir Twice Daily [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 trial evaluating twice-daily atazanavir for HIV infections. The trial was sponsored by Bristol-Myers Squibb.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• ATAZANAVIR (atazanavir)
• REYATAZ (atazanavir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections, Protease Inhibitor | Phase 1 | Status: COMPLETED